Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma

The Agreement Closes the Litigation Between the Parties

BOULDER, Colo., Aug. 29, 2025 /PRNewswire/ -- Foresight Diagnostics ("Foresight") today announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, "Roche") related to Foresight's patented PhasED-Seq™ technology. The agreement closes the litigation between the parties, with all claims against Foresight, its founders, and Stanford University dismissed with prejudice.

Under the terms of the agreement, Foresight has granted Roche a limited royalty-bearing non-exclusive sublicense under certain patents for use of PhasED-Seq for the development of in vitro diagnostic (IVD) kits for Non-Hodgkin's Lymphoma (NHL).

Intellectual property rights in the PhasED-Seq technology remain with Stanford University, with Foresight continuing to hold the exclusive license to the patents for all uses and geographies.

"We are pleased to have resolved our differences with Roche and to move forward with this licensing agreement, which provides Roche with tailored rights in the field of Non-Hodgkin's Lymphoma," said Jake Chabon, PhD, Chief Executive Officer of Foresight Diagnostics. "This resolution allows Foresight to remain focused on our mission to advance cutting-edge diagnostics aimed at improving outcomes for cancer patients worldwide."

More on EntSun News

• John Duffy Joins "Let's Talk Fabulous" Panel for The Eagle Obsession
• John Duffy Attends eZWay Network's Historic Ribbon Cutting Ceremony at the Epic Icon Center
• The Learning Circle Childcare Centre – South Surrey Campus Currently Enrolling for September & Fall
• Supernova Launches Global Auditions and Fundraiser to Fuel Pre-Debut Docuseries
• New Ownership, Same Heart: Jimmy & Jennifer Jhanda Take The Reins At Primos

About Foresight Diagnostics
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on X, LinkedIn, and Bluesky.

About PhasED-Seq™
The Foresight MRD platform is based on the Phased variant Enrichment and Detection by Sequencing (PhasED-Seq™) technology. PhasED-Seq lowers the error profile of mutation detection in sequencing data by requiring the concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (i.e., ctDNA) from healthy cell free DNA – enabling detection of ctDNA at levels below one part-per-million (<0.0001%). PhasED-Seq has been extensively tested in thousands of patient samples.

SOURCE Foresight Diagnostics, Inc.

---

Show All News | Report Violation